Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402.

Journal of the National Cancer Institute（2023）

引用 0|浏览7

暂无评分

摘要

Adding aflibercept to mFOLFOX6 induction was not associated with improved DFS or OS. Our findings suggested that CMS-IHC subtypes could be predictive of pCR with this treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要